Figure 1.

MPO was upregulated in CRC and correlated with the malignant progression of CRC patients. (A) The MPO expression levels in 480 tumor tissues and 41 normal tissues. (B) The expression of MPO in 41 normal and matched tumor tissues. (C) MPO expression in several cancers in the TIMER2 database. (D–F) The association with elevated MPO and clinicopathological characteristics, including M stages, pathological stage, and CEA level. (G–I) The association with elevated MPO and death events, including OS events, DSS events, and PFI events. The difference was considered significant at * P < 0.05, ** P < 0.01, or *** P < 0.001. ns, no significance.